Olanzapine combined with oxazepam in patients with schizophrenia and anxiety symptoms: A retrospective controlled study of dynamic changes in efficacy and safety

doi:10.3969/j.issn.1004-583X.2026.10.006

Abstract

Abstract:

Objective To compare the therapeutic efficacy of olanzapine combined with oxazepam (combination group) and olanzapine monotherapy (monotherapy group) in patients with schizophrenia and anxiety symptoms. Methods A total of 64 female patients with schizophrenia and anxiety symptoms of our hospital from January 2020 to December 2023 were retrospectively enrolled, with 32 patients in each group. Anxiety and psychotic symptoms were assessed using the Hamilton Anxiety Rating Scale (HAMA) and the Positive and Negative Syndrome Scale (PANSS), respectively, at baseline and at weeks 2, 4, and 8. The dynamic changes in treatment efficacy, correlations between symptom improvements, differences in response and remission rates, and adverse events during treatment were compared between the two groups. Results Significant main effects of time were observed for both HAMA and PANSS total scores. A significant group×time interaction was observed for the PANSS total score, with the combination group showing superior efficacy to the monotherapy group from week 2 onward. For HAMA, only the main effect of group was significant, whereas the group×time interaction was not statistically significant. Overall, no significant correlations were observed between changes in HAMA and PANSS scores during any assessment interval, except for a weak correlation between the reduction in HAMA score and the reduction in PANSS positive-symptom score from baseline to week 2. At week 4, the anxiety response rate was higher in the combination group than in the monotherapy group (71.88% vs 25.00%). By week 8, the anxiety response rate was 100.00% in both groups, whereas only 9.38% of patients in the combination group achieved anxiety remission. There was no statistically significant difference in the incidence of adverse events between the two groups. Conclusion Olanzapine combined with oxazepam may accelerate the early improvement of psychotic symptoms and enhance the early anxiety response in patients with schizophrenia and anxiety symptoms without increasing short-term adverse events. However, its benefit for long-term complete remission of anxiety appears limited, and improvements in anxiety and psychotic symptoms appear to be relatively independent. Therefore, short-term, early, and as-needed use of oxazepam in combination with olanzapine is recommended.

Key words: schizophrenia, anxiety, olanzapine, oxazepam, adverse reactions

CLC Number:

R749.3

Cai Fancan, Wu Haiqiang. Olanzapine combined with oxazepam in patients with schizophrenia and anxiety symptoms: A retrospective controlled study of dynamic changes in efficacy and safety[J]. Clinical Focus, 2026, 41(10): 910-915.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.10.006

https://www.lchc.cn/EN/Y2026/V41/I10/910

Figures/Tables 8

References 19

[1]	Fang X, Chen Y, Wang Y, et al. Depressive symptoms in schizophrenia patients: A possible relationship between SIRT1 and BDNF[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2019, 95:109673. doi:10.1016/j.pnpbp.2019.109673.
[2]	Zhao M, Ma J, Wu Y, et al. Depressive and anxiety symptoms among schizophrenia patients[J]. J Affect Disord, 2024, 362:749-754.doi:10.1016/J.JAD.2024.07.130.
[3]	于民权, 徐祥清. 5-HT2A/D2受体平衡拮抗剂NH809抗精神分裂症作用的初步研究[J]. 神经药理学报, 2022, 12(3): 1-4. doi:10.3969/j.issn.2095-1396.2022.03.001.
[4]	章瑜, 薛志敏. 苯二氮卓类药物的神经影像学研究[J]. 中国临床心理学杂志, 2009, 17(2):197-199.doi:10.16128/j.cnki.1005-3611.2009.02.013
[5]	陈熙明, 魏辰, 苏中华. 苯二氮卓类药物对认知功能的影响及相关机制[J]. 中国药物滥用防治杂志, 2023, 29(12):2071-2076+2088.doi:10.15900/j.cnki.zylf1995.2023.12.001.
[6]	吴海强, 蔡蕃灿, 朱美陈, 等. 奥氮平联合奥沙西泮治疗精神分裂症伴焦虑症状的效果[J]. 福建医药杂志, 2024, 46(7): 33-35. doi:10.20148/j.fmj.2024.07.010.
[7]	中华人民共和国国家卫生健康委员会. 精神障碍诊疗规范(2020年版)[M]. 北京: 人民卫生出版社, 2020:118-132.
[8]	吴旻熹, 洪语欣, 黄夏仪, 等. 精神分裂症的病理机制及治疗方法进展[J]. 广东药科大学学报, 2024, 40(6):136-143.doi:10.16809/j.cnki.2096-3653.2024040803.
[9]	李雨濛, 王怡冰, 申华, 等. 抑郁焦虑障碍伴失眠发病机制的研究进展[J]. 中国医药, 2025, 20(6): 940-944. doi:10.3760/j.issn.1673-4777.2025.06.030.
[10]	韦理强, 李坤. 焦虑和抑郁障碍的性别差异神经机制[J]. 科学通报, 2024, 69(30): 4470-4485. doi: 10.1360/TB-2024-0386.
[11]	王毅群, 王之琳, 李清杨, 等. 奥沙西泮的药理作用及机制研究进展[J]. 中国临床药理学与治疗学, 2026, 31(3):352-361. doi:10.12092/j.issn.1009-2501.2026.03.007.
[12]	Takekita Y, Tani H, Kawamata Y, et al. Pharmacological treatment of schizophrenia: Japanese expert consensus 2025.[J]. Schizophrenia(Heidelb), 2026, 12(1):70.doi:10.1038/S41537-026-00770-X.
[13]	王君, 修梅红, 王璇, 等. 1162例精神分裂症患者抗精神病药及镇静催眠药使用情况分析[J]. 中国药物依赖性杂志, 2024, 33(3):244-247+253.doi:10.13936/j.cnki.cjdd1992.2024.03.013.
[14]	陶涛, 张博宇, 郑爽, 等. 不同剂量奥氮平治疗老年抑郁障碍伴焦虑痛苦患者的疗效[J]. 医学临床研究, 2024, 41(3):336-339. doi:10.3969/j.issn.1671-7171.2024.03.005.
[15]	Nowak W, Korba P, Kinalska N, et al. Olanzapine in the treatment of schizophrenia in adolescents - mechanisms of action and therapeutic efficacy[J]. Psychiatr Pol, 2025, 59(6):1003-1015.doi:10.12740/PP/214532.
[16]	Park SY, Kim MG, Sung JH, et al. Atypical antipsychotic drug olanzapine inhibits 5-HT3 receptor-mediated currents by allosteric and non-competitive mechanisms[J]. Korean J Physiol Pharmacol, 2024, 29(4):431-442.doi:10.4196/KJPP.24.340.
[17]	Bailey RH, Davies E, Morrison JI. Oxazepam in the treatment of anxiety associated with depression: Results of treatment in 1600 cases(Studies in depression, VI)[J]. Curr Med Res Opin, 2008, 7(3):156-163.doi:10.1185/03007998109114256.
[18]	Li J, Chen F. Efficacy and safety evaluation of olanzapine treatment for schizophrenia patients: A retrospective data analysis[J]. Arch Psychiatr Nurs, 2025, 54:26-30.doi:10.1016/J.APNU.2024.12.005.
[19]	张景双, 夏玉平, 黄颖华, 等. 奥氮平所致药物不良反应的发生率及相关影响因素研究[J]. 中国现代应用药学, 2020, 37(11):1375-1379.doi:10.13748/j.cnki.issn1007-7693.2020.11.017.

变量	例数	年龄(岁)	病程(年)	奥氮平最终剂量(mg)	基线HAMA	基线PANSS总分
单药组	32	40.69±11.32	6.84±2.38	10.94±1.98	36.50±7.34	82.28±6.66
联合组	32	40.94±10.47	7.01±3.09	10.16±2.00	34.09±8.61	80.59±6.94
t值		-0.092	-0.247	1.569	1.203	0.993
P值		0.927	0.806	0.122	0.234	0.325

变量	例数	年龄(岁)	病程(年)	奥氮平最终剂量(mg)	基线HAMA	基线PANSS总分
单药组	32	40.69±11.32	6.84±2.38	10.94±1.98	36.50±7.34	82.28±6.66
联合组	32	40.94±10.47	7.01±3.09	10.16±2.00	34.09±8.61	80.59±6.94
t值		-0.092	-0.247	1.569	1.203	0.993
P值		0.927	0.806	0.122	0.234	0.325

量表	效应	F值	P值	η²P值
HAMA	组别主效应	8.410	0.005	0.119
	时间主效应	598.533	<0.01	0.906
	组别×时间交互	0.889	0.448	0.014
PANSS总分	组别主效应	34.609	<0.01	0.358
	时间主效应	1071.417	<0.01	0.945
	组别×时间交互	22.705	<0.01	0.268

量表	效应	F值	P值	η²P值
HAMA	组别主效应	8.410	0.005	0.119
	时间主效应	598.533	<0.01	0.906
	组别×时间交互	0.889	0.448	0.014
PANSS总分	组别主效应	34.609	<0.01	0.358
	时间主效应	1071.417	<0.01	0.945
	组别×时间交互	22.705	<0.01	0.268

组别	例数	HAMA				PANSS总分
组别	例数	基线	第2周	第4周	第8周	基线	第2周	第4周	第8周
单药组	32	36.50±7.34	27.53±5.72	19.91±3.95	12.91±1.91	82.28±6.66	73.28±4.99	65.78±4.38	56.72±4.42
联合组	32	34.09±8.61	23.59±6.86	15.81±3.17	9.88±1.86	80.59±6.94	67.88±5.05	57.56±3.76	46.50±3.59
t值		1.203	2.493	4.571	6.434	0.993	4.308	8.060	10.145
P值		0.234	0.015	<0.01	<0.01	0.325	<0.01	<0.01	<0.01